Kidney response rates from the study after 12 months are expected in the first half of 2013. A separate phase III study investigating the combination of Amigal and Fabrazyme, an currently approved therapy for Fabry disease from the Genzyme unit of Sanofi (SNY - Get Report), will report results in 2014.
-- Reported by Adam Feuerstein in Boston.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts